Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Hehlmann

Showing results (261-270 of 310) with videos related to

Pageof 31
Sort By:
Leukemia|August 30, 2002
Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon alphaK Merx, M C Müller, S Kreil, et al.
Leukemia|May 27, 2006
Gene expression signature of primary imatinib-resistant chronic myeloid leukemia patientsO Frank, B Brors, A Fabarius, et al.
Leukemia|September 13, 2003
Molecular monitoring of response to imatinib (Glivec) in CML patients pretreated with interferon alpha. Low levels of residual disease are associated with continuous remissionP Paschka, M C Müller, K Merx, et al.
Blood|September 15, 1996
A novel BCR-ABL fusion gene (e6a2) in a patient with Philadelphia chromosome-negative chronic myelogenous leukemiaA Hochhaus, A Reiter, H Skladny, et al.
Blood|February 15, 1996
Quantification of residual disease in chronic myelogenous leukemia patients on interferon-alpha therapy by competitive polymerase chain reactionA Hochhaus, F Lin, A Reiter, et al.
Leukemia|October 15, 2016
Which patients with myelofibrosis should receive ruxolitinib therapy? ELN-SIE evidence-based recommendationsM Marchetti, G Barosi, F Cervantes, et al.
Leukemia|April 18, 2006
Gene expression profiling of CD34+ cells identifies a molecular signature of chronic myeloid leukemia blast crisisC Zheng, L Li, M Haak, et al.
Leukemia|January 30, 2014
MDR1 expression predicts outcome of Ph+ chronic phase CML patients on second-line nilotinib therapy after imatinib failureM Agrawal, B Hanfstein, P Erben, et al.
Blood|December 23, 1999
Molecular heterogeneity in complete cytogenetic responders after interferon-alpha therapy for chronic myelogenous leukemia: low levels of minimal residual disease are associated with continuing remission. German CML Study Group and the UK MRC CML Study GroupA Hochhaus, A Reiter, S Saussele, et al.
Blood|September 9, 1999
An evidence-based analysis of the effect of busulfan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: developed for the American Society of HematologyR T Silver, S H Woolf, R Hehlmann, et al.
Pageof 31

Showing results (261-270 of 310) with videos related to

Sort By:
Pageof 31
Leukemia|August 30, 2002
Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon alphaK Merx, M C Müller, S Kreil, et al.
Leukemia|May 27, 2006
Gene expression signature of primary imatinib-resistant chronic myeloid leukemia patientsO Frank, B Brors, A Fabarius, et al.
Leukemia|September 13, 2003
Molecular monitoring of response to imatinib (Glivec) in CML patients pretreated with interferon alpha. Low levels of residual disease are associated with continuous remissionP Paschka, M C Müller, K Merx, et al.
Blood|September 15, 1996
A novel BCR-ABL fusion gene (e6a2) in a patient with Philadelphia chromosome-negative chronic myelogenous leukemiaA Hochhaus, A Reiter, H Skladny, et al.
Blood|February 15, 1996
Quantification of residual disease in chronic myelogenous leukemia patients on interferon-alpha therapy by competitive polymerase chain reactionA Hochhaus, F Lin, A Reiter, et al.
Leukemia|October 15, 2016
Which patients with myelofibrosis should receive ruxolitinib therapy? ELN-SIE evidence-based recommendationsM Marchetti, G Barosi, F Cervantes, et al.
Leukemia|April 18, 2006
Gene expression profiling of CD34+ cells identifies a molecular signature of chronic myeloid leukemia blast crisisC Zheng, L Li, M Haak, et al.
Leukemia|January 30, 2014
MDR1 expression predicts outcome of Ph+ chronic phase CML patients on second-line nilotinib therapy after imatinib failureM Agrawal, B Hanfstein, P Erben, et al.
Blood|December 23, 1999
Molecular heterogeneity in complete cytogenetic responders after interferon-alpha therapy for chronic myelogenous leukemia: low levels of minimal residual disease are associated with continuing remission. German CML Study Group and the UK MRC CML Study GroupA Hochhaus, A Reiter, S Saussele, et al.
Blood|September 9, 1999
An evidence-based analysis of the effect of busulfan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: developed for the American Society of HematologyR T Silver, S H Woolf, R Hehlmann, et al.
Pageof 31